Legend Biotech (LEGN) reported Q1 2026 revenue of $305.1 million, marking significant growth from previous quarters, but it recorded a net loss of $54.3 million and a basic EPS loss of $0.29. Despite a strong revenue trajectory—from $186.6 million in Q4 2024 to $305.1 million in Q1 2026—the company remains heavily invested, incurring a trailing net loss of $250.1 million over the last 12 months. Analysts anticipate a revenue growth rate of 27.3% annually and potential profitability in the next three years, albeit while navigating significant quarterly losses. Currently trading at a P/S of 4.7x—below the industry average—the stock reflects concerns over reliance on CARVYKTI and extensive R&D expenditures, creating a cautious outlook as the company strives for consistent profits and margin improvement.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-q1-loss-persists-and-tests-bullish-profi
